Molbio Diagnostics IPO GMP Surges to 21% as Molecular Diagnostics Company Prepares for Mega Launch
Goa-based molecular diagnostics firm Molbio Diagnostics is generating significant buzz in the grey market ahead of its Initial Public Offering (IPO) on August 10. With a latest Grey Market Premium (GMP) standing at 21.07 percent, investors are keenly watching the unlisted shares, which were tracking at approximately Rs 170.The strong indication from the GMP suggests a potential listing premium exceeding 21 percent based on the upper end of the price band. The IPO is scheduled to open for subscription on August 10 and conclude on August 12.
IPO Pricing and Financial Structure
Molbio Diagnostics has set the IPO price band between Rs 768 and Rs 807 per equity share. At the upper end of this band, the company is valued at around Rs 9,300 crore. The total fundraising target for the issue stands at Rs 939.7 crore.The offering structure includes a fresh issue of equity shares totaling Rs 200 crore. This is supplemented by an Offer For Sale (OFS) component amounting to Rs 739.7 crore, comprising 91.66 lakh shares. The OFS involves various existing shareholders and institutions, including Exxora Trading, Dr Chandrasekhar Bhaskaran Nair, and the investor India Business Excellence Fund managed by Motilal Oswal.
Investor Allocation and Application Details
Retail investors are given a minimum application size of 18 shares. At the upper end of the price band, this minimum investment amounts to Rs 14,526. Investors can bid for up to 13 lots, with a maximum potential investment calculated at Rs 1,88,838.A portion of equity shares worth Rs 1.5 crore has been reserved specifically for eligible employees. These employees will benefit from a discount of Rs 76 per share on the final issue price. The anchor investor segment is slated to open for one day on August 7.
Company Focus and Future Capex Plans
Molbio Diagnostics operates in the specialized field of molecular diagnostic solutions, covering roughly 30 diseases. These include critical areas such as tuberculosis, COVID-19, hepatitis B and C, human immunodeficiency virus (HIV), and human papillomavirus (HPV).The company has detailed plans for utilizing the fresh issue proceeds. A significant portion, Rs 105.5 crore, will be allocated to establishing a Centre of Excellence and an infrastructure facility dedicated to research and development. An additional Rs 72.2 crore is earmarked for purchasing plant, machinery, and equipment required for its manufacturing facilities in Goa and Visakhapatnam.
IPO Timeline and Book Running Management
The basis of allotment for the public issue is anticipated to be finalized on August 13. Molbio Diagnostics' shares are scheduled to make their debut on the stock exchanges on August 17. This high-profile offering is managed by several key entities, including Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors, who collectively serve as the book-running lead managers.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.